Intarcia racks up $225 mln

Boston-based biopharmaceutical company Intarcia Therapeutics has raised $225 million in synthetic royalty funding. According to terms of the deal, the investors, who were not named, will have the option to convert their synthetic royalty interests into Intarcia common stock at a $5.5 billion company valuation. Morgan Stanley & Co. LLC served as sole structuring agent to Intarcia on this transaction.

DealsNorth AmericaUSBriefs